Abstracts tagged "Cohort Study"

Abstract Number: 1761 • ACR Convergence 2022
Treatment Patterns of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis
Yinzhu Jin, Jun Liu, Rishi Desai and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Previous studies suggest that seropositive and seronegative rheumatoid arthritis (RA) patients may respond differently to disease-modifying anti-rheumatic drugs (DMARDs). However, little is known about…
Abstract Number: 2018 • ACR Convergence 2022
Five Year Follow-up of Systemic Disease Activity Measured with the ESSDAI in a Standard of Care Cohort of Patients with Primary Sjögren’s Syndrome
Liseth de Wolff¹, Suzanne Arends², Alja Stel³, Greetje van Zuiden³, Jolien van Nimwegen², Arjan Vissink⁴, Frans Kroese², Gwenny Verstappen² and Hendrika Bootsma², ¹UMCG, Zwolle, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands, ³University of Groningen, University Medical Centre Groningen, Groningen, Netherlands, ⁴University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background/Purpose: The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is often used as primary endpoint in randomised clinical trials (RCTs) in patients with primary Sjögren's…
Abstract Number: L06 • ACR Convergence 2021
Comparative Safety of Gout “Treat-to-target” and “Usual Care” Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Causal Inference Approach
Kazuki Yoshida, Jun Liu, Daniel Solomon, Robert J Glynn and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Rheumatology societies recommend serum-urate (SU)-driven treat-to-target (TTT) strategies for the management of gout. However, cardiovascular (CV) safety of urate-lowering therapy (ULT) has been questioned.…
Abstract Number: 0202 • ACR Convergence 2021
Variables Associated with Response to Therapy in Patients with Interstitial Pneumonia with Autoimmune Features
Elena Joerns¹, Traci Adams¹, Chad Newton¹, Lesley Davila², Kiran Batra¹, Jose Torrealba¹, Craig Glazer¹, Joan Reisch¹, Bonnie Bermas³, David Karp² and Una Makris⁴, ¹UT Southwestern, Dallas, TX, ²UT Southwestern Medical Center, Dallas, TX, ³UTSouthwestern Medical Center, Dallas, TX, ⁴UT Southwestern Medical Center, Dallas Veterans Administration, Dallas, TX
Background/Purpose: We have limited knowledge of the characteristics of patients with interstitial pneumonia with autoimmune features (IPAF) that are associated with response to immunosuppression. Thus,…
Abstract Number: 0679 • ACR Convergence 2021
Cardiovascular Risk Associated with Treatment of Allopurinol and Benzbromarone in Patients with Gout
Yeonghee Eun, Seonyoung Kang, Seulkee Lee, Hyungjin Kim, Jaejoon Lee, Eun-Mi Koh and Hoon-Suk Cha, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
Background/Purpose: Previous studies have shown that cardiovascular risk is increased in patients with gout. There are many studies on the effect of uric acid lowering…
Abstract Number: 1217 • ACR Convergence 2021
Discontinuation Rate of Tofacitinib Is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients: Pooled Data from Two Rheumatoid Arthritis Registries in Canada
Mohammad Movahedi¹, Denis Choquette², Louis Coupal², Angela Cesta³, Xiuying Li³, Edward Keystone⁴ and Claire Bombardier⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ³Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, ⁴Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁵University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment as the first or an alternative option to biologic disease-…
Abstract Number: 1749 • ACR Convergence 2021
Treatment Patterns in Latin American Patients with Lupus Nephritis over a 20-year Period
Rosana quintana¹, Jose Gomez Puerta², Guillermina Harvey³, Marina Scolnik⁴, Nidia Meras⁵, Cintia Otaduy⁶, Maria Salinas⁷, Valeria Arturi⁸, Maria Sattler⁹, Rosa Serrano Morales¹, Luciana Gonzalez Lucero¹⁰, Wilfredo Grageda¹¹, Nicolas Perez¹², Cecilia Nora Pisoni¹³, Simone Appenzeller¹⁴, Ana Silva¹⁵, Odirlei Andre Monticielo¹⁶, Henrique Moriz¹⁷, Francinne Ribiero¹⁸, Emily Figueiredo Neves Yuki Yuki¹⁹, Edgard Neto²⁰, Iris Guerra²¹, Paula Burgos²², Milena Mimica²³, Gustavo Aroca²⁴, Gabriel Tobon²⁵, Luis Gonzalez²⁶, Gerardo Quintana-López²⁷, Andres Bonfanti²⁴, RAFAEL LOPEZ²⁸, Luis Jara Quezada²⁹, Margarita Portela-Hernandez³⁰, HILDA FRAGOSO LOYO³¹, Luis H Silveira³², Ignacio Garcia-De La Torre³³, Carlos Abud-Mendoza³⁴, Jorge Esquivel-Valerio³⁵, Jonathan Losanto³⁶, Astrid Paats³⁷, JORGE CIEZA CALDERON³⁸, Manuel Ugarte-Gil³⁹, Katiuzka Zuniga Corrales⁴⁰, Roberto Munoz⁴¹, Ernesto Cairoli⁴², Gonzalo Silveira⁴³, Luis Catoggio⁴⁴, Ashley Orillion⁴⁵, Chetan Karyekar⁴⁶, Federico Zazzetti⁴⁷ and Bernardo A. Pons-Estel⁴⁸, ¹Grupo Oroño. Centro Regional de Enfermedades Autoinmunes y Reumaticas (GO-CREAR), Rosario, Argentina, ²Hospital Clinic, University of Barcelona, Barcelona, Spain, ³Instituto de Investigaciones Teóricas y Aplicadas. Facultad de Ciencias Económicas y Estadistica. Universidad Nacional de Rosario, Rosario, Argentina, ⁴Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Hospital Italiano de Córdoba, Córdoba, Argentina, ⁶Hospital Córdoba, Cordoba, Argentina, ⁷Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ⁸Hospital HIGA San Martín, La Plata, Argentina, ⁹Sanatorio Británico, Cordoba, Argentina, ¹⁰Janssen Cilag Farmaceutica SA, Tucuman, Argentina, ¹¹Hospital General de Agudos J.M. Ramos Mejía, Buenos Aires, Argentina, ¹²Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina, ¹³CEMIC, Buenos Aires, Argentina, ¹⁴Hospital das Clínicas da Universidade Estadual de Campinas, Campinas, Brazil, ¹⁵UFG, GOIANIA, Goias, Brazil, ¹⁶Serviço de Reumatologia do Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ¹⁷Hospital das Clinicas, Universidade Federal de Pernambuco, Pernambuco, Brazil, ¹⁸Hospital Universitario Pedro Ernesto, UERJ, Rio de Janeiro, Brazil, ¹⁹Hospital Das Clinicas da Faculdade de Medicina da USP, São Paulo, Brazil, ²⁰UNIFESP, São Paulo, Brazil, ²¹Hospital del Salvador, Santiago, Chile, ²²Facultad de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile, ²³Universidad San Sebastián, Santiago, Chile, ²⁴Clínica de la Costa Ltda., Barranquilla, Colombia, ²⁵Fundación Valle del Lili, Cali, Colombia, ²⁶Universidad de Antioquia, Medellin, Colombia, ²⁷Reumavance Group, Rheumatology section, Department of Internal Medicine, Fundación Santa Fe de Bogotá University Hospital; Department of Internal Medicine, School of Medicine, Universidad Nacional de Colombia; Department of Internal Medicine, School of Medicine, Universidad de Los Andes, Bogota, Colombia, ²⁸Hospital Luis Vernaza, Guayaquil, Ecuador, ²⁹Centro Médico La Raza, Mexico City DF, Mexico, ³⁰IMSS, Mexico Df, Mexico, ³¹INCMNSZ, Tlalpan, Mexico, ³²Instituto Nacional de Cardiologia, Mexico City, Mexico, ³³Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, ³⁴Hospital Central “Dr Ignacio Morones Prieto”, Unidad Regional de Reumatología y Osteoporosis, Hospital Central and Facultad de Medicina de la Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ³⁵University Hospital Dr. Jose Eleuterio Gonzalez, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ³⁶Hospital de Clínicas I, San Lorenzo, Paraguay, ³⁷Hospital de Clinicas, Asuncion, Paraguay, ³⁸Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, ³⁹Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ⁴⁰Hospital Cayetano Heredia, Lima, Peru, ⁴¹Hospital Docente Padre Billini, Santo Domingo, Dominican Republic, ⁴²Autoimmune Diseases Unit, Centro Asistencial del Sindicato Médico del Uruguay (CASMU) and Hospital Evangélico, Montevideo, Uruguay, ⁴³Hospital Señor del Milagro, Salta, Argentina, ⁴⁴Hospital Italiano de Buenos Aires, Olivos, Argentina, ⁴⁵Global Commercial Strategic Organisation, Johnson and Johnson, Horsham, PA, ⁴⁶Janssen R&D, Spring House, PA, ⁴⁷Medical Affairs, Jan-Cil Argentina, Buenos Aires, Argentina, ⁴⁸Grupo Oroo - Centro Regional de Enfermedades Autoinmunes y Reumticas (GO-CREAR), Rosario, Argentina
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex and heterogeneous autoimmune disease. Over the last decade, changes have occurred in the treatment of these patients,…
Abstract Number: 0211 • ACR Convergence 2021
Unsupervised Machine-learning Algorithms for the Identification of Clinical Phenotypes in the Osteoarthritis Initiative Database
David Demanse¹, László B. Tankó², Patrick Lustenberger³, Philipp Nikolaus³, Ilja Rasin³, Damian F. Brennan³, Franziska Saxer², Ronenn Roubenoff⁴, Sumehra Premji¹, Philip Conaghan⁵ and Matthias Schieker⁴, ¹Novartis Pharma AG, Basel, Switzerland, ²Novartis Institutes for Biomedical Research, Basel, Switzerland, ³IBM Switzerland AG, Zürich, Switzerland, ⁴Novartis Institutes for Biomedical Research, Basel, Switzerland, Basel, Switzerland, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Osteoarthritis (OA) is a chronic disabling disease, for which there are only limited treatment options. One major challenge in the development of effective treatment…
Abstract Number: 0723 • ACR Convergence 2021
Size of Regression to the Mean in First-Line Interventions for Osteoarthritis: An Illusion of Effectiveness
Martin Englund and Aleksandra Turkiewicz, Lund University, Lund, Sweden
Background/Purpose: Persons who seek treatment for osteoarthritis (OA) are likely doing so when experiencing a flare-up in pain. Due to natural fluctuation of pain, this…
Abstract Number: 1233 • ACR Convergence 2021
Physician and Patient Reported Effectiveness Outcomes Are Similar in Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Registry in Canada
Mohammad Movahedi¹, Angela Cesta², Xiuying Li², Edward Keystone³ and Claire Bombardier⁴, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, ³Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁴University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment as an alternative option to biologic disease modifying antirheumatic drugs…
Abstract Number: 1759 • ACR Convergence 2021
An Analysis of Medication Responsiveness Based on Subtype and Race Within a Cohort of Cutaneous Lupus Erythematosus Patients
Emily Keyes¹, Anisha Jobanputra², Madison Grinnell³, Rui Feng⁴, Thomas Vazquez⁵, DeAnna Diaz⁶ and Victoria Werth⁷, ¹Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ²Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, OMAHA, NE, ⁴University of Pennsylvania Department of Biostatistics, Philadelphia, PA, ⁵FIU Wertheim College of Medicine, Virginia Beach, VA, ⁶Philadelphia College of Medicine, Philadelphia, PA, ⁷Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cutaneous lupus erythematosus (CLE) can present in association with or without concomitant SLE, and with skin manifestations varying by subtype – acute CLE, subacute…
Abstract Number: 0214 • ACR Convergence 2021
Baseline Cam or Pincer Morphology Is Associated with Loss of Quantitative Joint Space Width at the Hip: The Johnston County Osteoarthritis Project
Amanda Nelson¹, Carolina Alvarez¹, Yvonne Golightly¹, Jamie Stiller², Jordan Renner¹, Nigel Arden³, Charles Ratzlaff⁴ and Jeffrey Duryea⁵, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Alamance Regional Medical Center, Durham, NC, ³University of Oxford, Oxford, United Kingdom, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵Brigham and Women's Hospital, Boston, MA
Background/Purpose: To determine the association between radiographic cam and pincer morphology and loss of hip quantitative joint space width (qJSW) in a community-based cohort.Methods: Data…
Abstract Number: 0793 • ACR Convergence 2021
Contributing Factors of Good Outcome in Difficult-to-treat Rheumatoid Arthritis: A Multicenter RA Ultrasound Prospective Observational Cohort Study in Japan
Shin-ya Kawashiri¹, Tohru Michitsuji¹, Yushiro Endo¹, Ayako Nishino¹, Toshimasa Shimizu¹, Remi Sumiyoshi¹, Tomohiro Koga¹, Naoki Iwamoto¹, Kunihiro Ichinose² and Atsushi Kawakami¹, ¹Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan
Background/Purpose: The concept of difficult-to-treat rheumatoid arthritis (D2T RA) has emerged as the greatest unmet need in recent years. We have investigated the clinical characteristics…
Abstract Number: 1311 • ACR Convergence 2021
De Novo Psoriasis Can Be Reported at Any Timepoint in Early Axial Spondyloarthritis: An Analysis of 6 Years of Follow-up of the DESIR Cohort
Florian LUCASSON¹, Pascal Richette², krystel aouad¹, Adeline RUYSSEN-WITRAND³, Daniel Wendling⁴, Bruno Fautrel⁵ and Laure Gossec⁶, ¹Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France, ²Lariboisiere Hospital, Paris, France, ³Toulouse University Hospital, Centre d'Investigation Clinique de Toulouse CIC1436, Inserm, Paul Sabatier University,, Toulouse, France, ⁴Service de rhumatologie, CHU de Besançon, Besançon, France, ⁵Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France, ⁶Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France
Background/Purpose: Psoriasis is a frequent extra-articular manifestation in axial spondyloarthritis (axSpA) with a prevalence in established axSpA around 9% and consequences on the disease course.…
Abstract Number: 1800 • ACR Convergence 2021
Altered Metabolic Profiles in the Transition from Psoriasis to Psoriatic Arthritis: A Longitudinal Analysis
Ananta Paine¹, Paul Brookes², Dongmei Li³, Somyaroop Bhattacharya⁴, Maria de la Luz Garcia-Hernandez¹ and Christopher Ritchlin¹, ¹Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ²Department of Pharmacology & Physiology, University of Rochester Medical Center, Rochester, NY, ³Department of Clinical and Translational Research, University of Rochester Medical Center, Rochester, NY, ⁴Division of Neonatology, Department of Pediatrics, University of Rochester, Rochester, NY
Background/Purpose: The transition to psoriatic arthritis (PsA) occurs in 20-30% of psoriasis (Ps) patients, but the mechanisms underlying the emergence of musculoskeletal disease are not…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].